FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088349747> ?p ?o ?g. }

• W2088349747 endingPage "396" @default.
• W2088349747 startingPage "388" @default.
• W2088349747 abstract "The human prostatic carcinoma cell line DU145 has previously been found to be resistant to treatment with TNF-family ligands. However, TRAIL, TNF-alpha and anti-Fas antibodies (Ab) treatment in combination with the histone deacetylase inhibitor Trichostatin A (TSA) converted the phenotype of DU145 from resistant to sensitive. TSA induced 15% cell death but simultaneous treatment with TRAIL, TNF-alpha and anti-Fas Ab resulted in 55%, 70% and 40% cell death, respectively. Simultaneous treatment did not increase the level of TSA-induced histone acetylation, but induced the release of acetylated histones from chromatin into the cytosol. This release was caspase dependent since it was abrogated by Z-VAD-fmk. In addition, treatment with TSA induced caspase-9 activation and resulted in the release of cytochrome c and Smac/DIABLO from mitochondria. To further investigate the role of caspase-9 in TSA-mediated apoptosis we used two different approaches: (1) cells were pretreated with the caspase-9 inhibitor Z-LEHD-fmk, and (2) cells were transfected with a dominant-negative form of caspase-9. Both approaches gave similar results: cells became resistant to treatment with TSA. These data indicate that TSA mediates its effect via the mitochondrial pathway. This was confirmed by examining DU145 overexpressing Bcl-2. These transfectants were resistant to TSA treatment. Taken together, our data shows that only simultaneous treatment with TNF-family ligands and TSA in DU145 resulted in caspase activity sufficient to induce apoptosis. The combination of TSA and TNF-family ligands could potentially be the basis for the treatment of prostate cancer." @default.
• W2088349747 created "2016-06-24" @default.
• W2088349747 creator A5013326292 @default.
• W2088349747 creator A5045503018 @default.
• W2088349747 creator A5047517759 @default.
• W2088349747 creator A5055426569 @default.
• W2088349747 creator A5067589372 @default.
• W2088349747 date "2005-04-01" @default.
• W2088349747 modified "2023-10-18" @default.
• W2088349747 title "Trichostatin a (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment" @default.
• W2088349747 cites W1527449265 @default.
• W2088349747 cites W1546653512 @default.
• W2088349747 cites W1626483287 @default.
• W2088349747 cites W1673314361 @default.
• W2088349747 cites W1931140155 @default.
• W2088349747 cites W1964617786 @default.
• W2088349747 cites W1966176339 @default.
• W2088349747 cites W1967705708 @default.
• W2088349747 cites W1970856815 @default.
• W2088349747 cites W1974090542 @default.
• W2088349747 cites W1976141746 @default.
• W2088349747 cites W1978044485 @default.
• W2088349747 cites W1979377700 @default.
• W2088349747 cites W1979603257 @default.
• W2088349747 cites W1994582326 @default.
• W2088349747 cites W1994705026 @default.
• W2088349747 cites W1995902306 @default.
• W2088349747 cites W1998549696 @default.
• W2088349747 cites W2001110380 @default.
• W2088349747 cites W2003939380 @default.
• W2088349747 cites W2008597649 @default.
• W2088349747 cites W2013848847 @default.
• W2088349747 cites W2025128734 @default.
• W2088349747 cites W2030571655 @default.
• W2088349747 cites W2034207297 @default.
• W2088349747 cites W2041376033 @default.
• W2088349747 cites W2054260525 @default.
• W2088349747 cites W2069460795 @default.
• W2088349747 cites W2070421413 @default.
• W2088349747 cites W2071715575 @default.
• W2088349747 cites W2088218587 @default.
• W2088349747 cites W2098641105 @default.
• W2088349747 cites W2100273455 @default.
• W2088349747 cites W2111640802 @default.
• W2088349747 cites W2147220700 @default.
• W2088349747 cites W2151501496 @default.
• W2088349747 cites W2158239005 @default.
• W2088349747 cites W2167490100 @default.
• W2088349747 cites W2189820974 @default.
• W2088349747 cites W2317698610 @default.
• W2088349747 doi "https://doi.org/10.4161/cbt.4.4.1615" @default.
• W2088349747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15846101" @default.
• W2088349747 hasPublicationYear "2005" @default.
• W2088349747 type Work @default.
• W2088349747 sameAs 2088349747 @default.
• W2088349747 citedByCount "23" @default.
• W2088349747 countsByYear W20883497472012 @default.
• W2088349747 countsByYear W20883497472013 @default.
• W2088349747 countsByYear W20883497472014 @default.
• W2088349747 countsByYear W20883497472016 @default.
• W2088349747 countsByYear W20883497472019 @default.
• W2088349747 countsByYear W20883497472021 @default.
• W2088349747 countsByYear W20883497472023 @default.
• W2088349747 crossrefType "journal-article" @default.
• W2088349747 hasAuthorship W2088349747A5013326292 @default.
• W2088349747 hasAuthorship W2088349747A5045503018 @default.
• W2088349747 hasAuthorship W2088349747A5047517759 @default.
• W2088349747 hasAuthorship W2088349747A5055426569 @default.
• W2088349747 hasAuthorship W2088349747A5067589372 @default.
• W2088349747 hasBestOaLocation W20883497471 @default.
• W2088349747 hasConcept C104317684 @default.
• W2088349747 hasConcept C121608353 @default.
• W2088349747 hasConcept C153911025 @default.
• W2088349747 hasConcept C185592680 @default.
• W2088349747 hasConcept C190283241 @default.
• W2088349747 hasConcept C2776202225 @default.
• W2088349747 hasConcept C2776438761 @default.
• W2088349747 hasConcept C2777865847 @default.
• W2088349747 hasConcept C2778305200 @default.
• W2088349747 hasConcept C2779723316 @default.
• W2088349747 hasConcept C31573885 @default.
• W2088349747 hasConcept C48297814 @default.
• W2088349747 hasConcept C502942594 @default.
• W2088349747 hasConcept C54009773 @default.
• W2088349747 hasConcept C54355233 @default.
• W2088349747 hasConcept C55493867 @default.
• W2088349747 hasConcept C64927066 @default.
• W2088349747 hasConcept C81885089 @default.
• W2088349747 hasConcept C86803240 @default.
• W2088349747 hasConcept C96232424 @default.
• W2088349747 hasConcept C98424977 @default.
• W2088349747 hasConceptScore W2088349747C104317684 @default.
• W2088349747 hasConceptScore W2088349747C121608353 @default.
• W2088349747 hasConceptScore W2088349747C153911025 @default.
• W2088349747 hasConceptScore W2088349747C185592680 @default.
• W2088349747 hasConceptScore W2088349747C190283241 @default.
• W2088349747 hasConceptScore W2088349747C2776202225 @default.
• W2088349747 hasConceptScore W2088349747C2776438761 @default.

• next